{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T05:22:18Z","timestamp":1731734538142,"version":"3.28.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"DOI":"10.7759\/cureus.73727","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:59:11Z","timestamp":1731664751000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety Profile of Biosimilar Polyethylene Glycol (PEG)-Asparaginase (Asviia) in Patients With Acute Leukemia: A Retrospective Study From Kashmir"],"prefix":"10.7759","author":[{"given":"Faisal","family":"R Guru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rukhsana","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumail","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ahmed","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohmad Hussain","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafirah","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulfat","family":"Ara Wani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Childhood Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae): Health Professional Version","author":"PDQ Pediatric Treatment Editorial Board","year":"2024","unstructured":"PDQ Pediatric Treatment Editorial Board. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US), Bethesda, MD; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: Progress through collaboration","volume":"33","author":"Pui CH","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, et al.. Childhood acute lymphoblastic leukemia: Progress through collaboration. J Clin Oncol. 2015, 33:2938-48. 10.1200\/JCO.2014.59.1636","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.187591","article-title":"Acute leukemia in children: A review of the current Indian data","volume":"5","author":"Arora RS","year":"2016","unstructured":"Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian J Cancer. 2016, 5:155-60. 10.4103\/2278-330X.187591","journal-title":"South Asian J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong WH","year":"2014","unstructured":"Tong WH, Pieters R, Kaspers GJ, et al.. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014, 123:2026-33. 10.1182\/blood-2013-10-534347","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu CH","year":"2007","unstructured":"Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother. 2007, 8:1977-84. 10.1517\/14656566.8.12.1977","journal-title":"Expert Opin Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S245210","article-title":"Clinical Utility of Pegaspargase in children, adolescents and young adult patients with acute lymphoblastic leukemia: A review","volume":"11","author":"Bender C","year":"2021","unstructured":"Bender C, Maese L, Carter-Febres M, Verma A. Clinical Utility of Pegaspargase in children, adolescents and young adult patients with acute lymphoblastic leukemia: A review. Blood Lymphat Cancer. 2021, 11:25-40. 10.2147\/BLCTT.S245210","journal-title":"Blood Lymphat Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.9.3s.32886","article-title":"Pegylation: Engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineux G","year":"2003","unstructured":"Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy. 2003, 23:3S-8S. 10.1592\/phco.23.9.3s.32886","journal-title":"Pharmacotherapy"},{"key":"ref8","article-title":"Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase","volume":"24","author":"Yu-tong Z","year":"2014","unstructured":"Yu-tong Z, Li-hua F, Xiao-dan Z, Li-zhe W, Jian C. Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase. Iran J Pediatr. 2014, 24:75-80.","journal-title":"Iran J Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future","volume":"44","author":"Avramis VI","year":"2005","unstructured":"Avramis VI, Panosyan EH. Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet. 2005, 44:367-93. 10.2165\/00003088-200544040-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149129","article-title":"L-asparaginase and PEG asparaginase\u2014Past, present, and future","volume":"10 Suppl","author":"Keating MJ","year":"1993","unstructured":"Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase\u2014Past, present, and future. Leuk Lymphoma. 1993, 10 Suppl:153-7. 10.3109\/10428199309149129","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"Egler RA","year":"2016","unstructured":"Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016, 7:62-71. 10.4103\/0976-500X.184769","journal-title":"J Pharmacol Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221998738","article-title":"Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions","volume":"28","author":"Santos AC","year":"2022","unstructured":"Santos AC, Land MG, Lima EC. Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions. J Oncol Pharm Pract. 2022, 28:551-9. 10.1177\/1078155221998738","journal-title":"J Oncol Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1218004","article-title":"Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review","volume":"58","author":"Beaupin LK","year":"2017","unstructured":"Beaupin LK, Bostrom B, Barth MJ, et al.. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review. Leuk Lymphoma. 2017, 58:766-72. 10.1080\/10428194.2016.1218004","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf PA","year":"2007","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007, 12:991-8. 10.1634\/theoncologist.12-8-991","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0410-5","article-title":"Population pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar(\u00ae) in children with acute lymphoblastic leukemia","volume":"42","author":"W\u00fcrthwein G","year":"2017","unstructured":"W\u00fcrthwein G, Lanvers-Kaminsky C, Hempel G, et al.. Population pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar(\u00ae) in children with acute lymphoblastic leukemia. Eur J Drug Metab Pharmacokinet. 2017, 42:955-63. 10.1007\/s13318-017-0410-5","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1774806","article-title":"A pilot study conducted at a tertiary cancer care center, evaluating the serum asparaginase activity in children suffering from acute lymphoblastic leukemia after the administration of biosimilar Pegaspargase","volume":"45","author":"Venkatagiri AM","year":"2024","unstructured":"Venkatagiri AM, Bhat VK, Asok A, Prabhu K. A pilot study conducted at a tertiary cancer care center, evaluating the serum asparaginase activity in children suffering from acute lymphoblastic leukemia after the administration of biosimilar Pegaspargase. Indian J Med Paediatr Oncol. 2024, 45:390-5. 10.1055\/s-0043-1774806","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235547","article-title":"A single dose of PEG-asparaginase at the beginning of induction not only accelerates MRD clearance but also improves long-term outcome in children with B-lineage ALL","volume":"15","author":"Popov A","year":"2023","unstructured":"Popov A, Henze G, Roumiantseva J, et al.. A single dose of PEG-asparaginase at the beginning of induction not only accelerates MRD clearance but also improves long-term outcome in children with B-lineage ALL. Cancers. 2023, 15:5547. 10.3390\/cancers15235547","journal-title":"Cancers"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.793.793","article-title":"Outstanding outcome for children with standard risk-low (SR-Low) acute lymphoblastic leukemia (ALL) and no benefit to intensified Peg-asparaginase (PEG-ASNase) therapy: Results of Children\u2019s Oncology Group (COG) Study AALL0331","volume":"124","author":"Mattano LA","year":"2014","unstructured":"Mattano LA, Devidas M, Friedmann AM, et al.. Outstanding outcome for children with standard risk-low (SR-Low) acute lymphoblastic leukemia (ALL) and no benefit to intensified Peg-asparaginase (PEG-ASNase) therapy: Results of Children\u2019s Oncology Group (COG) Study AALL0331. Blood. 2014, 124:793. 10.1182\/blood.V124.21.793.793","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss I","year":"2016","unstructured":"Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016, 96:375-80. 10.1111\/ejh.12600","journal-title":"Eur J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2019.01.013","article-title":"PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: A systematic review","volume":"42","author":"Medawar CV","year":"2020","unstructured":"Medawar CV, Mosegui GB, Vianna CM, Costa TM. PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: A systematic review. Hematol Transfus Cell Ther. 2020, 42:54-61. 10.1016\/j.htct.2019.01.013","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis IM","year":"2016","unstructured":"van der Sluis IM, Vrooman LM, Pieters R, et al.. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016, 101:279-85. 10.3324\/haematol.2015.137380","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0129-1","article-title":"Allergic reactions associated with intravenous versus intramuscular Pegaspargase: A retrospective chart review","volume":"17","author":"Abbott LS","year":"2015","unstructured":"Abbott LS, Zakova M, Shaikh F, Shewaramani N, Punnett A, Dupuis LL. Allergic reactions associated with intravenous versus intramuscular Pegaspargase: A retrospective chart review. Paediatr Drugs. 2015, 17:315-21. 10.1007\/s40272-015-0129-1","journal-title":"Paediatr Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26200","article-title":"Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review","volume":"64","author":"Hasan H","year":"2017","unstructured":"Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. Pediatr Blood Cancer. 2017, 64:81-8. 10.1002\/pbc.26200","journal-title":"Pediatr Blood Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2024.03.001","article-title":"Peg-asparaginase associated toxicities in children with acute lymphoblastic leukemia: A single-center cross-sectional study","volume":"9","author":"Awwad S","year":"2024","unstructured":"Awwad S, Abu Alnasr R, Almanjomi F, Al Sultan M, Howaidi J, Almotairi M, AlFayyad I. Peg-asparaginase associated toxicities in children with acute lymphoblastic leukemia: A single-center cross-sectional study. Pediatric Hematology Oncology Journal. 2024, 9:54-62. 10.1016\/j.phoj.2024.03.001","journal-title":"Pediatric Hematology Oncology Journal"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: A review in acute lymphoblastic leukaemia","volume":"79","author":"Heo YA","year":"2019","unstructured":"Heo YA, Syed YY, Keam SJ. Pegaspargase: A review in acute lymphoblastic leukaemia. Drugs. 2019, 79:767-77. 10.1007\/s40265-019-01120-1","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05789-7","article-title":"Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia","volume":"103","author":"T\u00f6lle M","year":"2024","unstructured":"T\u00f6lle M, G\u00f6kbuget N, Habringer S, Keller U, Schwartz S. Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia. Ann Hematol. 2024, 103:3269-71. 10.1007\/s00277-024-05789-7","journal-title":"Ann Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen LT","year":"2015","unstructured":"Henriksen LT, Harila-Saari A, Ruud E, et al.. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015, 62:427-33. 10.1002\/pbc.25319","journal-title":"Pediatr Blood Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock W","year":"2011","unstructured":"Stock W, Douer D, DeAngelo DJ, et al.. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011, 52:2237-53. 10.3109\/10428194.2011.596963","journal-title":"Leuk Lymphoma"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte R","year":"2021","unstructured":"Schulte R, Hinson A, Huynh V, et al.. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021, 10:7551-60. 10.1002\/cam4.4281","journal-title":"Cancer Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310992-efficacy-and-safety-profile-of-biosimilar-polyethylene-glycol-peg-asparaginase-asviia-in-patients-with-acute-leukemia-a-retrospective-study-from-kashmir","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:59:13Z","timestamp":1731664753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310992-efficacy-and-safety-profile-of-biosimilar-polyethylene-glycol-peg-asparaginase-asviia-in-patients-with-acute-leukemia-a-retrospective-study-from-kashmir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.73727","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}